These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 16353926)

  • 1. Challenges in the transition to model-based development.
    Grasela TH; Fiedler-Kelly J; Walawander CA; Owen JS; Cirincione BB; Reitz KE; Ludwig EA; Passarell JA; Dement CW
    AAPS J; 2005 Oct; 7(2):E488-95. PubMed ID: 16353926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.
    Chien JY; Friedrich S; Heathman MA; de Alwis DP; Sinha V
    AAPS J; 2005 Oct; 7(3):E544-59. PubMed ID: 16353932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactive visualization and communication for increased impact of pharmacometrics.
    Krause A; Gieschke R
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):140S-145S. PubMed ID: 20881227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fostering culture and optimizing organizational structure for implementing model-based drug development.
    Zhang L; Allerheiligen SR; Lalonde RL; Stanski DR; Pfister M
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):146S-150S. PubMed ID: 20881228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacometrics and the transition to model-based development.
    Grasela TH; Dement CW; Kolterman OG; Fineman MS; Grasela DM; Honig P; Antal EJ; Bjornsson TD; Loh E
    Clin Pharmacol Ther; 2007 Aug; 82(2):137-42. PubMed ID: 17632539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six Sigma: not for the faint of heart.
    Benedetto AR
    Radiol Manage; 2003; 25(2):40-53. PubMed ID: 12800564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Informatics: the fuel for pharmacometric analysis.
    Grasela TH; Fiedler-Kelly J; Cirincione B; Hitchcock D; Reitz K; Sardella S; Smith B
    AAPS J; 2007 Mar; 9(1):E84-91. PubMed ID: 17408238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of process analytical technology to crystallization processes.
    Yu LX; Lionberger RA; Raw AS; D'Costa R; Wu H; Hussain AS
    Adv Drug Deliv Rev; 2004 Feb; 56(3):349-69. PubMed ID: 14962586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
    Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA
    Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of pharmacophore modeling in drug design.
    Guner OF
    IDrugs; 2005 Jul; 8(7):567-72. PubMed ID: 15973565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective.
    Chaikin P; Rhodes GR; Bruno R; Rohatagi S; Natarajan C
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1428-38. PubMed ID: 11185663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A; Hoffman A
    J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Connecting the dots: role of standardization and technology sharing in biological simulation.
    Ghosh S; Matsuoka Y; Kitano H
    Drug Discov Today; 2010 Dec; 15(23-24):1024-31. PubMed ID: 20934535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of modeling and simulation tools for the evaluation of biocatalytic processes: a future perspective.
    Sin G; Woodley JM; Gernaey KV
    Biotechnol Prog; 2009; 25(6):1529-38. PubMed ID: 19768802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling the 3D structure of GPCRs: advances and application to drug discovery.
    Becker OM; Shacham S; Marantz Y; Noiman S
    Curr Opin Drug Discov Devel; 2003 May; 6(3):353-61. PubMed ID: 12833668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.